TY  - JOUR
A1  - Gore, Lia
A1  - Locatelli, Franco
A1  - Zugmaier, Gerhard
A1  - Handgretinger, Rupert
A1  - O’Brien, Maureen M.
A1  - Bader, Peter
A1  - Bhojwani, Deepa
A1  - Schlegel, Paul-Gerhardt
A1  - Tuglus, Catherine A.
A1  - Stackelberg, Arend von
T1  - Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
T2  - Blood cancer journal
N2  - Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Pediatric patients with disease refractory to last chemotherapy, relapse after allogeneic hematopoietic stem-cell transplantation (alloHSCT), or second or further relapse have a particularly poor prognosis. Intensive chemotherapy followed by alloHSCT after achieving remission can result in cure for some patients. However, survival is still low with this approach. Thus, additional treatment modalities with acceptable toxicity are needed to improve long-term survival. ...
KW  - Acute lymphocytic leukaemia
KW  - Immunotherapy
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/46970
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-469706
SN  - 2044-5385
N1  - Rights and permissions: Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
VL  - 8
IS  - 9, Art. 80
SP  - 1
EP  - 7
PB  - Nature Publishing Group
CY  - London [u. a.]
ER  -